The impact of curcumin (320 mg/day) was tested in a placebo-controlled phase 3 clinical trial in proteinuric CKD patients with or without diabetes, but no effects on Nrf2 activation, antioxidant enzyme activity, proteinuria, eGFR, or lipid profile were reported (NCT01831193) [262]. The gene discussed is NFE2L2; the disease is diabetes mellitus.